|
Volumn 6, Issue 9, 2000, Pages 3621-3628
|
Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: Enhanced activity when combined with taxol chemotherapy
a a a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
HU3S193;
IODINE 131;
MONOCLONAL ANTIBODY;
PACLITAXEL;
UNCLASSIFIED DRUG;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANTIBODY LABELING;
ARTICLE;
BREAST CANCER;
CANCER INHIBITION;
CANCER RADIOTHERAPY;
CONTROLLED STUDY;
DRUG EFFICACY;
GROWTH INHIBITION;
HUMAN;
HUMAN CELL;
IMMUNE RESPONSE;
INFLAMMATION;
MAXIMUM PERMISSIBLE DOSE;
METASTASIS;
MOUSE;
NONHUMAN;
NUDE MOUSE;
PRIORITY JOURNAL;
RADIATION DOSE;
RADIOIMMUNOTHERAPY;
TUMOR GROWTH;
ADENOCARCINOMA;
ANIMALS;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS, PHYTOGENIC;
BREAST NEOPLASMS;
CELL DIVISION;
COMBINED MODALITY THERAPY;
DOSE-RESPONSE RELATIONSHIP, RADIATION;
FEMALE;
HUMANS;
IMMUNOTOXINS;
IODINE RADIOISOTOPES;
LEWIS BLOOD-GROUP SYSTEM;
MICE;
MICE, INBRED BALB C;
MICE, NUDE;
PACLITAXEL;
RADIOIMMUNOTHERAPY;
TUMOR CELLS, CULTURED;
XENOGRAFT MODEL ANTITUMOR ASSAYS;
|
EID: 0033818002
PISSN: 10780432
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
Times cited : (60)
|
References (29)
|